Day 3

Day Three: Wednesday, February 1

8:15 am Pharmaceutical Leaders’ Breakfast

MORNING PLENARY KEYNOTE SESSION
Considering Drug Development Decisions a Financial Investment

9:00 am Chairperson’s Review of Day Two 

	9:15 am Defining a Framework for Assessing R&D Risk and its Key Drivers
• How do technical, commercial, operational, and post-marketing risk impact   pharmaceutical projects? • How does risk affect a project's likelihood of success and its value? • What do benchmarking data tell us about risk and risk management? • What are the keys to improving risk management? Richard J. Heaslip, Ph.D., Vice President, Project & Portfolio Management, Wyeth Research

	10:00 am INTERACTIVE PANEL: Reducing the Cost of Attrition - Fact or Fiction?
• Getting through the Phase 2 choke • De-Risking your portfolio  • Mix of innovative vs. precedented targets • Internal vs. external development Moderator: Shama Kajiji, Ph.D., MBA, Director, Worldwide Project Management, Head, Attrition Analysis Office, PGRD, Pfizer

10:45 am Networking Coffee Break

	11:15 am Optimizing the Pharmaceutical R&D Portfolio; Balancing for Focus or for Diversity?
• How to accurately assess risk and value for projects and therapeutic areas  • Apportioning resources to ensure optimal product flow  • Should you focus or should you diversify the portfolio?  Christine Cioffe, Ph.D., Vice President, R&D Portfolio Management, Merck & Co.

12:00 pm Beyond the Spreadsheet: What Will Drive Shareholder Value? The Business of Science and the Future of Pharma - An Investor Perspective

• Are factors beyond the spreadsheet increasingly driving perceptions of    shareholder value? • What are the effects of a stricter Phase IV environment and evolving FDA    approval process; of pipeline status; of patent expiry; and of ethical    concerns about the industry? • How are partnership evaluated by investors? • How has the emergence of large biotech affected the market? • Can the industry continue as we know it? T. Forcht Dagi, MD, MPH, MBA, FACS, The Harvard-MIT Division of Health Sciences and Technology, Managing Director, Echelon Ventures

	12:45 pm Luncheon Presentation Summit Wrap-Up
Nick Hughes, PA Consulting

2:00 pm Close of Pharmaceutical Leaders’ Summit